{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T02:14:34Z","timestamp":1768529674450,"version":"3.49.0"},"reference-count":31,"publisher":"Hindawi Limited","issue":"5","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":730,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dermatol Ther"],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.1111\/dth.12087","type":"journal-article","created":{"date-parts":[[2015,10,13]],"date-time":"2015-10-13T05:24:08Z","timestamp":1444713848000},"page":"400-403","source":"Crossref","is-referenced-by-count":17,"title":["Topical and oral bexarotene"],"prefix":"10.1155","volume":"26","author":[{"given":"Courtney R.","family":"Schadt","sequence":"first","affiliation":[{"name":"Medicine (Dermatology); University of Louisville; Louisville Kentucky"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"98","published-online":{"date-parts":[[2013,10,4]]},"reference":[{"key":"10.1111\/dth.12087-BIB0001|dth12087-cit-0001","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1101\/gad.6.3.329","article-title":"Characterization of three RXR genes that mediate the action of 9-cis retinoic acid","volume":"6","author":"Mangelsdorf","year":"1992","journal-title":"Genes Dev"},{"key":"10.1111\/dth.12087-BIB0002|dth12087-cit-0002","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1038\/358771a0","article-title":"Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors","volume":"358","author":"Kliewer","year":"1992","journal-title":"Nature"},{"key":"10.1111\/dth.12087-BIB0003|dth12087-cit-0003","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1111\/j.1396-0296.2003.01644.x","article-title":"Retinoids: therapeutic applications and mechanisms of action in cutaneous T-cell lymphoma","volume":"16","author":"Zhang","year":"2003","journal-title":"Dermatol Ther"},{"key":"10.1111\/dth.12087-BIB0004|dth12087-cit-0004","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/bjd.12042","article-title":"UK consensus statement on safe clinical prescribing of bexarotene for patients with cutaneous T-cell lymphoma","volume":"168","author":"Scarisbrick","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1111\/dth.12087-BIB0005|dth12087-cit-0005","first-page":"1234","article-title":"Induction of apoptosis by bexarotene in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action","volume":"8","author":"Zhang","year":"2002","journal-title":"Clin Cancer Res"},{"key":"10.1111\/dth.12087-BIB0006|dth12087-cit-0006","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1001\/archderm.141.3.315","article-title":"Biological effects of bexarotene in cutaneous T-cell lymphoma","volume":"141","author":"Budgin","year":"2005","journal-title":"Arch Dermatol"},{"key":"10.1111\/dth.12087-BIB0007|dth12087-cit-0007","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/j.1365-2133.2008.08931.x","article-title":"Bexarotene activates the p53\/p73 pathway in human cutaneous T-cell lymphoma","volume":"160","author":"Nieto-Rementeria","year":"2009","journal-title":"Br J Dermatol"},{"key":"10.1111\/dth.12087-BIB0008|dth12087-cit-0008","first-page":"581","article-title":"Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma","volume":"137","author":"Duvic","year":"2001","journal-title":"Arch Dermatol"},{"key":"10.1111\/dth.12087-BIB0009|dth12087-cit-0009","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1200\/JCO.2001.19.9.2456","article-title":"Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results","volume":"19","author":"Duvic","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1111\/dth.12087-BIB0010|dth12087-cit-0010","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1067\/mjd.2002.124607","article-title":"Optimizing bexarotene therapy for cutaneous T-cell lymphoma","volume":"47","author":"Talpur","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/dth.12087-BIB0011|dth12087-cit-0011","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1001\/archderm.139.6.771","article-title":"Psoralen plus long-wave UV-A (PUVA) and bexarotene therapy: an effective and synergistic combined adjunct to therapy for patients with advanced cutaneous T-cell lymphoma","volume":"139","author":"McGinnis","year":"2003","journal-title":"Arch Dermatol"},{"key":"10.1111\/dth.12087-BIB0012|dth12087-cit-0012","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.jaad.2003.10.669","article-title":"Low-dose oral bexarotene in combination with low-dose interferon alfa in the treatment of cutaneous T-cell lymphoma: clinical synergism and possible immunologic mechanisms","volume":"50","author":"McGinnis","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/dth.12087-BIB0013|dth12087-cit-0013","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1182\/blood-2004-11-4570","article-title":"A phase-1 trial of bexarotene and denileukin diftitox in patients with relapsed or refractory cutaneous T-cell lymphoma","volume":"106","author":"Foss","year":"2005","journal-title":"Blood"},{"key":"10.1111\/dth.12087-BIB0014|dth12087-cit-0014","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1080\/09546630802562427","article-title":"Evaluation of the efficacy of the combination of oral bexarotene and methotrexate for the treatment of early stage treatment-refractory cutaneous T-cell lymphoma","volume":"20","author":"Kannangara","year":"2009","journal-title":"J Dermatolog Treat"},{"key":"10.1111\/dth.12087-BIB0015|dth12087-cit-0015","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1002\/cncr.22596","article-title":"Results of a phase II trial of oral bexarotene (Targretin) combined with interferon alfa-2b (Intron-A) for patients with cutaneous T-cell lymphoma","volume":"109","author":"Straus","year":"2007","journal-title":"Cancer"},{"key":"10.1111\/dth.12087-BIB0016|dth12087-cit-0016","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.trim.2011.06.008","article-title":"Donor lymphocyte infusions combined with systemic PUVA\/bexarotene as an effective bimodal immunologic approach in a patient with relapsed cutaneous T cell lymphoma after allogeneic stem cell transplantation","volume":"25","author":"Schlaak","year":"2011","journal-title":"Transpl Immunol"},{"key":"10.1111\/dth.12087-BIB0017|dth12087-cit-0017","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.clml.2011.06.016","article-title":"Bexarotene is active against subcutaneous panniculitis-like T-cell lymphoma in adult and pediatric populations","volume":"12","author":"Mehta","year":"2012","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1111\/dth.12087-BIB0018|dth12087-cit-0018","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.jaad.2009.03.014","article-title":"Folliculotropic mycosis fungoides: clinicopathological features and outcome in a series of 20 cases","volume":"62","author":"Muniesa","year":"2010","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/dth.12087-BIB0019|dth12087-cit-0019","doi-asserted-by":"crossref","first-page":"e190","DOI":"10.1016\/j.leukres.2011.06.029","article-title":"Primary cutaneous CD30 positive anaplastic large cell lymphoma - report of a case treated with bexarotene","volume":"35","author":"Oliveira","year":"2011","journal-title":"Leuk Res"},{"key":"10.1111\/dth.12087-BIB0020|dth12087-cit-0020","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.jaad.2002.08.001","article-title":"A phase II multicenter clinical trial of systemic bexarotene in psoriasis","volume":"51","author":"Smit","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/dth.12087-BIB0021|dth12087-cit-0021","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1111\/j.1365-2141.2009.07596.x","article-title":"Hypertriglyceridaemia with bexarotene in cutaneous T cell lymphoma: the role of omega-3 fatty acids","volume":"145","author":"Musolino","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1111\/dth.12087-BIB0022|dth12087-cit-0022","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1056\/NEJM199904083401404","article-title":"Central hypothyroidism associated with retinoid X receptor-selective ligands","volume":"340","author":"Sherman","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1111\/dth.12087-BIB0023|dth12087-cit-0023","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1007\/s00280-010-1553-0","article-title":"Interactions of bexarotene (LGD1069, Targretin) with the coagulation system","volume":"68","author":"Hespel","year":"2011","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1111\/dth.12087-BIB0024|dth12087-cit-0024","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1001\/archderm.138.3.325","article-title":"Phase 1 and 2 trial of bexarotene gel for skin-directed treatment of patients with cutaneous T-cell lymphoma","volume":"138","author":"Breneman","year":"2002","journal-title":"Arch Dermatol"},{"key":"10.1111\/dth.12087-BIB0025|dth12087-cit-0025","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/S0190-9622(03)01475-0","article-title":"Topical bexarotene therapy for patients with refractory or persistent early-stage cutaneous T-cell lymphoma: results of the phase III clinical trial","volume":"49","author":"Heald","year":"2003","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/dth.12087-BIB0026|dth12087-cit-0026","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1046\/j.1365-2133.2003.05729.x","article-title":"Novel treatment of chronic severe hand dermatitis with bexarotene gel","volume":"150","author":"Hanifin","year":"2004","journal-title":"Br J Dermatol"},{"key":"10.1111\/dth.12087-BIB0027|dth12087-cit-0027","first-page":"501","article-title":"Phase II clinical trial of bexarotene gel 1% in psoriasis","volume":"6","author":"Breneman","year":"2007","journal-title":"J Drugs Dermatol"},{"key":"10.1111\/dth.12087-BIB0028|dth12087-cit-0028","doi-asserted-by":"crossref","first-page":"592 e1","DOI":"10.1016\/j.jaad.2009.02.037","article-title":"Phase I\/II randomized bilateral half-head comparison of topical bexarotene 1% gel for alopecia areata","volume":"61","author":"Talpur","year":"2009","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/dth.12087-BIB0029|dth12087-cit-0029","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1159\/000068451","article-title":"Bexarotene is a new treatment option for lymphomatoid papulosis","volume":"206","author":"Krathen","year":"2003","journal-title":"Dermatology"},{"key":"10.1111\/dth.12087-BIB0030|dth12087-cit-0030","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jaad.2005.09.012","article-title":"A randomized, double-blind, vehicle-controlled, bilateral comparison trial of bexarotene gel 1% versus vehicle gel in combination with narrowband UVB phototherapy for moderate to severe psoriasis vulgaris","volume":"54","author":"Magliocco","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/dth.12087-BIB0031|dth12087-cit-0031","first-page":"169","article-title":"Folliculotropic mycosis fungoides responding to bexarotene gel","volume":"7","author":"Walling","year":"2008","journal-title":"J Drugs Dermatol"}],"container-title":["Dermatologic Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fdth.12087","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/dth.12087\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T18:00:30Z","timestamp":1671818430000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/dth.12087"}},"subtitle":["Bexarotene efficacy and side effects"],"short-title":[],"issued":{"date-parts":[[2013,9]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013,9]]}},"URL":"https:\/\/doi.org\/10.1111\/dth.12087","archive":["Portico"],"relation":{},"ISSN":["1396-0296"],"issn-type":[{"value":"1396-0296","type":"print"}],"subject":[],"published":{"date-parts":[[2013,9]]}}}